The strong revenue growth and profitability, driven by the Melinta acquisition and DefenCath sales, combined with the $75M buyback and reiterated guidance, suggest confidence in future performance. Traders should monitor upcoming Phase 3 data for Rezzayo in Q2 2026 as a key catalyst.
CRMD drugs
CRMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $6.30entry
- T+1 · 9mo ago +2.54%α +3.85% · $6.46
- T+5 · 8mo ago +1.59%α +3.82% · $6.40
- T+20 · 8mo ago +11.90%α +15.69% · $7.05
- T+60 · 6mo ago +34.13%α +22.83% · $8.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix reported strong Q4 2025 financial results with $128.6 million in revenue, driven by DefenCath and the recent Melinta acquisition, and achieved full-year revenue of $311.7 million ($401.3 million pro forma). The company posted net income of $163.0 million and reiterated 2026 guidance of $300-$320 million in revenue and $100-$125 million in adjusted EBITDA, while announcing a $75 million share repurchase program.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $128.6 million, up from $31.2 million in Q4 2024
- Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million
- Q4 2025 net income was $14.0 million; full-year net income was $163.0 million
- Adjusted EBITDA for Q4 2025 was $77.2 million, up from $15.3 million in Q4 2024
- Company reiterated 2026 guidance: $300-$320 million revenue and $100-$125 million adjusted EBITDA
- Board approved $75 million share repurchase program
- Cash and short-term investments totaled $148.5 million at year-end
Financial Impact
Q4 revenue grew 312% YoY to $128.6M; full-year revenue was $311.7M with pro forma of $401.3M; net income turned from $17.9M loss in 2024 to $163.0M profit in 2025
Segment Breakdown
| Segment | Revenue |
|---|---|
| DefenCath | $91.2M |
| Melinta portfolio | $37.4M |
Risk Factors
- Revenue growth is heavily influenced by the Melinta acquisition, making YoY comparisons difficult
- Future performance depends on successful integration of Melinta and clinical trial outcomes
- The $42.4M tax expense in Q4 was due to utilization of deferred tax assets, which may not recur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-023881 |
| Document: ea027968001-8k_cormedix.htm | 0001213900-26-023881 |
| Document: 0001213900-26-023881-index-headers.html | 0001213900-26-023881 |
| Document: 0001213900-26-023881-index.html | 0001213900-26-023881 |
| Document: 0001213900-26-023881.txt | 0001213900-26-023881 |
Track record
21 reports on CRMD
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers